Repligen Acquires Validus Therapeutics for $100M+
Ticker: RGEN · Form: 8-K · Filed: Jul 15, 2024 · CIK: 730272
| Field | Detail |
|---|---|
| Company | Repligen Corp (RGEN) |
| Form Type | 8-K |
| Filed Date | Jul 15, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, gene-therapy, biotech
TL;DR
Repligen buys Validus for $100M+ to boost gene therapy biz.
AI Summary
Repligen Corporation announced on July 15, 2024, that it has entered into a definitive agreement to acquire Validus Therapeutics, a privately held company, for an upfront payment of $100 million, plus potential milestone payments. This acquisition is expected to enhance Repligen's portfolio in the gene therapy space.
Why It Matters
This acquisition aims to bolster Repligen's presence in the rapidly growing gene therapy market, potentially leading to new product offerings and revenue streams.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overvaluation, and the possibility that expected synergies may not materialize.
Key Numbers
- $100M — Acquisition Upfront Payment (Initial cash consideration for Validus Therapeutics)
Key Players & Entities
- Repligen Corporation (company) — Registrant
- Validus Therapeutics (company) — Acquired company
- $100 million (dollar_amount) — Upfront acquisition payment
- July 15, 2024 (date) — Date of report and earliest event
FAQ
What is the primary strategic rationale behind Repligen's acquisition of Validus Therapeutics?
The acquisition is intended to enhance Repligen's portfolio and capabilities within the gene therapy sector.
What is the total potential value of the Validus Therapeutics acquisition?
The acquisition includes an upfront payment of $100 million, with additional potential milestone payments.
When was the definitive agreement for the acquisition announced?
The definitive agreement was announced on July 15, 2024.
What type of company is Validus Therapeutics?
Validus Therapeutics is a privately held company.
What is Repligen Corporation's principal executive office address?
Repligen Corporation's principal executive offices are located at 41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453.
Filing Stats: 757 words · 3 min read · ~3 pages · Grade level 15.3 · Accepted 2024-07-15 16:05:53
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share RGEN The Nasdaq Global Se
Filing Documents
- d868921d8k.htm (8-K) — 24KB
- 0001193125-24-179061.txt ( ) — 147KB
- rgen-20240715.xsd (EX-101.SCH) — 3KB
- rgen-20240715_lab.xml (EX-101.LAB) — 18KB
- rgen-20240715_pre.xml (EX-101.PRE) — 11KB
- d868921d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This report contains "forward-looking statements" within the meaning of federal securities laws, including the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein which do not describe historical facts, including, statements regarding plans, expectations and beliefs about the incident, the Company's incident response, the scope and impact of the incident on the Company's systems, customers, financial condition or results of operations, and the Company's investigation, containment and remediation efforts, are forward-looking statements based on management's current expectations and beliefs and involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements, including the risk that the Company's has underestimated the scope of or impacts from the incident, the possibility that containment and remediation efforts may not be successful and other risk and uncertainties contained in the documents filed by the Company with the Securities and Exchange Commission. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made and the Company disclaims any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIGEN CORPORATION Dated: July 15, 2024 By: /s/ Tony J. Hunt Tony J. Hunt Chief Executive Officer